Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stanley Erck
Pharma
With vax uptake slow, Novavax adjusts revenue projection to $2B
Novavax has adjusted its revenue projection for 2022. Instead of guiding to a range of $2B to $2.3B, the company estimates revenue will be $2B.
Kevin Dunleavy
Nov 9, 2022 9:36am
FDA signs off on Novavax COVID-19 shot for booster use
Oct 20, 2022 9:00am
Novavax finally submits its COVID-19 vaccine to the FDA
Jan 31, 2022 3:55pm
Novavax can forget U.S., but shot can still be a global force
Jun 22, 2021 10:18am
With vax success, Novavax execs rack up $106M in stock options
Apr 30, 2021 10:34am
Rejuvenated Novavax ramps up to produce billions of COVID shots
Mar 3, 2021 10:23am
